Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 31;12(1):9.
doi: 10.1186/s13317-021-00152-6.

Potential clinical biomarkers in rheumatoid arthritis with an omic approach

Yolima Puentes-Osorio  1   2 , Pedro Amariles  3 , Miguel Ángel Calleja  4 , Vicente Merino  4 , Juan Camilo Díaz-Coronado  5 , Daniel Taborda  6
Affiliations
Review

Potential clinical biomarkers in rheumatoid arthritis with an omic approach

Yolima Puentes-Osorio et al. Auto Immun Highlights. .

Abstract

Objective: To aid in the selection of the most suitable therapeutic option in patients with diagnosis of rheumatoid arthritis according to the phase of disease, through the review of articles that identify omics biological markers.

Methods: A systematic review in PubMed/Medline databases was performed. We searched articles from August 2014 to September 2019, in English and Spanish, filtered by title and full text; and using the terms "Biomarkers" AND "Rheumatoid arthritis".

Results: This article supplies an exhaustive review from research of objective measurement, omics biomarkers and how disease activity appraise decrease unpredictability in treatment determinations, and finally, economic, and clinical outcomes of treatment options by biomarkers' potential influence. A total of 122 articles were included. Only 92 met the established criteria for review purposes and 17 relevant references about the topic were included as well. Therefore, it was possible to identify 196 potential clinical biomarkers: 22 non-omics, 20 epigenomics, 33 genomics, 21 transcriptomics, 78 proteomics, 4 glycomics, 1 lipidomics and 17 metabolomics.

Conclusion: A biomarker is a measurable indicator of some, biochemical, physiological, or morphological condition; evaluable at a molecular, biochemical, or cellular level. Biomarkers work as indicators of physiological or pathological processes, or as a result of a therapeutic management. In the last five years, new biomarkers have been identified, especially the omics, which are those that proceed from the investigation of genes (genomics), metabolites (metabolomics), and proteins (proteomics). These biomarkers contribute to the physician choosing the best therapeutic option in patients with rheumatoid arthritis.

Keywords: Biomarkers; Genomics; Metabolomics; Omics; Pharmacogenomics; Polymorphism; Proteomics; Rheumatoid arthritis; Stages; Treatment.

PubMed Disclaimer

Conflict of interest statement

Authors declare they do not have any conflict of interest.

Figures

Fig. 1
Fig. 1
Phases of rheumatoid arthritis, treatment phases and omics biomarkers
Fig. 2
Fig. 2
Flow diagram for screening and evidence selection. *The repeated article was excluded due to the biomarker having a different end up, and it may disturb the results of the study. *The articles that had little statistical power were not conclusive, and the statistical evaluation did not confirm the use of the biomarker. *The articles that had many limitations were excluded because the impossibility to find the optimal selection method, and factor omission which can affect the outcome. *The articles related to treating the subject with little force were also excluded due to lack of information between the treatment and the use of the biomarkers.
See this image and copyright information in PMC

References

    1. Takeuchi T. Biomarkers as a treatment guide in rheumatoid arthritis. Clin Immunol. 2018;186:59–62. doi: 10.1016/j.clim.2017.07.019. - DOI - PubMed
    1. Atkinson AJ, Colburn WA, DeGruttola VG, DeMets DL, Downing GJ, Hoth DF, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95. doi: 10.1067/mcp.2001.113989. - DOI - PubMed
    1. Nakamura S, Suzuki K, Iijima H, Hata Y, Lim CR, Ishizawa Y, et al. Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study. Arthritis Res Ther. 2016;18(1):1–12. doi: 10.1186/s13075-016-1052-8. - DOI - PMC - PubMed
    1. Arora A, Mahajan A, Spurden D, Boyd H, Porter D. Long-term drug survival of TNF inhibitor therapy in RA patients: a systematic review of european national drug registers. Int J Rheumatol. 2013 doi: 10.1155/2013/764518. - DOI - PMC - PubMed
    1. Agarwal SK, Glass RJ, Shadick NA, Coblyn JS, Anderson RJ, Maher NE, et al. Predictors of discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritis. J Rheumatol. 2008;35(9):1737–1744. - PMC - PubMed

LinkOut - more resources